REGN

701.42

0.80% -5.64

시간 외 거래: 702.10 0.68 +0.10%

리제네론 파마슈티컬스 (REGN)

개요 뉴스 가격 이력 옵션 체인 Financials REGN 왜 하락? 토론 예측

전일 마감가:

$707.06

열려 있는:

$703.02

하루 거래량:

728.88K

Relative Volume:

1.03

시가총액:

$73.54B

수익:

$14.92B

순이익/손실:

$4.42B

주가수익비율:

17.09

EPS:

41.0422

순현금흐름:

$3.79B

1주 성능:

-6.67%

1개월 성능:

-9.76%

6개월 성능:

+7.61%

1년 성능:

+18.88%

1일 변동 폭

$700.26

$714.48

1주일 범위

$668.85

$756.40

52주 변동 폭

$476.49

$821.11

리제네론 파마슈티컬스 Stock (REGN) Company Profile

명칭

Regeneron Pharmaceuticals Inc

부문

Healthcare (1113)

산업

Biotechnology (622)

전화

(914) 847-7000

주소

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

직원

15,410

트위터

@regeneron

다음 수익 날짜

2026-04-29

최신 SEC 제출 서류

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
REGN Regeneron Pharmaceuticals Inc	701.42	74.13B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	423.92	108.71B	12.07B	3.95B	3.19B	15.33
ARGX Argen X Se Adr	783.50	48.61B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	41.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.81B	5.36B	287.73M	924.18M	2.5229

리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-31	재개	Piper Sandler	Overweight
2026-03-06	개시	Barclays	Overweight
2026-01-07	업그레이드	BofA Securities	Underperform → Buy
2025-12-03	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	개시	HSBC Securities	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Perform
2025-08-14	개시	Rothschild & Co Redburn	Buy
2025-06-30	다운그레이드	Argus	Buy → Hold
2025-05-30	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	다운그레이드	Wells Fargo	Overweight → Equal Weight
2025-05-14	업그레이드	Citigroup	Neutral → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-02-05	업그레이드	Leerink Partners	Market Perform → Outperform
2025-01-16	다운그레이드	UBS	Buy → Neutral
2024-12-10	재개	BofA Securities	Underperform
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Neutral
2024-09-24	다운그레이드	Leerink Partners	Outperform → Market Perform
2024-03-12	개시	Bernstein	Outperform
2024-01-12	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	개시	Deutsche Bank	Hold
2023-11-03	업그레이드	Raymond James	Mkt Perform → Outperform
2023-08-21	업그레이드	Canaccord Genuity	Hold → Buy
2023-08-21	재확인	Oppenheimer	Perform
2023-06-28	다운그레이드	Canaccord Genuity	Buy → Hold
2023-03-27	업그레이드	SVB Securities	Market Perform → Outperform
2023-03-24	업그레이드	Jefferies	Hold → Buy
2023-03-23	업그레이드	Raymond James	Underperform → Mkt Perform
2023-01-30	업그레이드	Cowen	Market Perform → Outperform
2023-01-20	업그레이드	JP Morgan	Neutral → Overweight
2022-10-26	다운그레이드	Raymond James	Mkt Perform → Underperform
2022-10-17	다운그레이드	Evercore ISI	Outperform → In-line
2022-09-09	업그레이드	Jefferies	Underperform → Hold
2022-09-09	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-06-06	개시	Jefferies	Underperform
2022-05-23	개시	SVB Leerink	Outperform
2022-01-05	다운그레이드	BofA Securities	Neutral → Underperform
2022-01-03	업그레이드	Bernstein	Mkt Perform → Outperform
2021-12-15	다운그레이드	Bernstein	Outperform → Mkt Perform
2021-12-09	재개	Wells Fargo	Overweight
2021-12-07	재개	Cowen	Market Perform
2021-12-06	개시	Goldman	Buy
2021-11-19	재개	BMO Capital Markets	Outperform
2021-11-05	다운그레이드	The Benchmark Company	Buy → Hold
2021-06-29	개시	H.C. Wainwright	Buy
2021-01-25	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-01-13	업그레이드	The Benchmark Company	Hold → Buy
2021-01-08	업그레이드	Citigroup	Neutral → Buy
2020-10-05	업그레이드	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	다운그레이드	The Benchmark Company	Buy → Hold
2020-07-09	업그레이드	SunTrust	Hold → Buy
2020-05-26	업그레이드	Wells Fargo	Equal Weight → Overweight
2020-04-28	다운그레이드	Citigroup	Buy → Neutral
2020-04-17	업그레이드	The Benchmark Company	Hold → Buy
2020-04-08	개시	The Benchmark Company	Hold
2020-03-31	개시	Wolfe Research	Peer Perform
2020-02-27	개시	Barclays	Overweight
2020-02-26	업그레이드	Canaccord Genuity	Hold → Buy
2020-02-26	다운그레이드	Robert W. Baird	Outperform → Neutral
2020-02-25	업그레이드	Jefferies	Hold → Buy
2020-02-11	업그레이드	Argus	Hold → Buy
2019-12-24	개시	Raymond James	Mkt Perform
2019-12-16	다운그레이드	Evercore ISI	Outperform → In-line
2019-12-13	업그레이드	Credit Suisse	Neutral → Outperform
2019-11-12	개시	SunTrust	Hold
2019-11-07	업그레이드	Citigroup	Neutral → Buy
2019-10-17	재개	BofA/Merrill	Neutral
2019-09-23	업그레이드	Guggenheim	Neutral → Buy

모두보기

리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스

May 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00 - MarketBeat

May 01, 2026

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - BioPharma Dive

May 01, 2026

Wealthfront Advisers LLC Purchases 2,202 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 01, 2026

State of New Jersey Common Pension Fund D Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 01, 2026

Danske Bank A S Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 01, 2026

Apr 30, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 30, 2026

Regeneron Presses Amgen for Eylea Antitrust Damages Evidence - Bloomberg Law News

Apr 30, 2026

Royal Bank Of Canada Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat

Apr 30, 2026

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.

Apr 30, 2026

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings - Benzinga

Apr 30, 2026

REGN Maintained by Barclays -- Price Target Lowered to $917 - GuruFocus

Apr 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $917.00 Price Target at Barclays - MarketBeat

Apr 30, 2026

Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923 - marketscreener.com

Apr 30, 2026

Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913 - marketscreener.com

Apr 30, 2026

Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00 - MarketBeat

Apr 30, 2026

REGN Maintains by Truist Securities -- Price Target Lowered to $796 - GuruFocus

Apr 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $800.00 Price Target at Wells Fargo & Company - MarketBeat

Apr 30, 2026

RBC Trims Price Target on Regeneron Pharmaceuticals to $762 From $779, Keeps Sector Perform Rating - marketscreener.com

Apr 30, 2026

REGN Maintained by Wells Fargo -- Price Target Lowered to $800 - GuruFocus

Apr 30, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CA - MarketBeat

Apr 30, 2026

Regeneron achieves 1st-qtr 2026 double-digit growth - The Pharma Letter

Apr 30, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

Regeneron Q1 2026 net income falls 10% to $727m - Yahoo Finance

Apr 30, 2026

Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Highl - GuruFocus

Apr 30, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MSN

Apr 30, 2026

Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis

Apr 30, 2026

REGN SWOT Analysis: Financial Strength and Growth Opportunities Revealed in 10-Q Filing - GuruFocus

Apr 30, 2026

3 Healthcare Stocks We Keep Off Our Radar - The Globe and Mail

Apr 30, 2026

Apr 29, 2026

Research Alert: CFRA Retains Buy Rating On Shares Of Regeneron Pharmaceuticals, Inc. - Moomoo

Apr 29, 2026

Why (REGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Apr 29, 2026

Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st

Apr 29, 2026

Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU - MSN

Apr 29, 2026

Regeneron wins FDA approval for hearing loss therapy - MSN

Apr 29, 2026

Truist cuts Regeneron stock price target on FDA approval delay By Investing.com - Investing.com Canada

Apr 29, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat

Apr 29, 2026

Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's

Apr 29, 2026

Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat

Apr 29, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results - MarketBeat

Apr 29, 2026

Why Regeneron (REGN) Shares Are Getting Obliterated Today - TradingView

Apr 29, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8%Here's What Happened - MarketBeat

Apr 29, 2026

Regeneron Pharmaceuticals Delivers 19% Revenue Growth in Q1 2026 - AlphaStreet

Apr 29, 2026

Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey

Apr 29, 2026

Raymond James cuts Regeneron stock price target on Eylea HD miss - Investing.com Canada

Apr 29, 2026

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe - Benzinga

Apr 29, 2026

Regeneron Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet

Apr 29, 2026

Regeneron shares fall 5% on Eylea sales decline, regulatory delays By Investing.com - Investing.com Canada

Apr 29, 2026

Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 29, 2026

Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness - Reuters

Apr 29, 2026

Intel, NXP Semiconductors, Seagate, Bloom Energy, Avis, Regeneron, Robinhood, and More Stock Movers - Barron's

Apr 29, 2026

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength - Yahoo Finance

Apr 29, 2026

Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation - Yahoo Finance

Apr 29, 2026